Northway Biotech
16.11.2023 14:21:41 CET | ACCESS Newswire | Press release
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X to Present at the Small Cap Growth Virtual Investor Conference June 4th1.6.2026 15:30:00 CEST | Press release
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com CALGARY, AB / ACCESS Newswire / June 1, 2026 / Karbon-X Corp. (OTCQB:KARX), based in Calgary, Alberta focused on global carbon markets and climate infrastructure solutions, today announced that Chad Clovis, Chief Executive Officer will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on June 4, 2026 DATE: June 4th TIME: 10:00 AM ET REGISTER HERE Available for 1x1 meetings: June 5th-9th Schedule 1x1 Meetings here. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive
Resin Solutions LLC Introduces "Stratix(TM)" Brand Architecture for Products Serving the Aerospace and Defense Applications1.6.2026 15:00:00 CEST | Press release
EXTON, PA / ACCESS Newswire / June 1, 2026 / Resin Solutions LLC, a leading provider of advanced material solutions, today announced the launch of Stratix™, a new brand identity reflecting the company's deepened strategic focus on the Aerospace and Defense sector. This new designation underscores the company's long-term commitment to supporting the unique and demanding requirements of aerospace and defense customers. By clearly bringing both its existing and in-development aerospace and defense products under the Stratix™ brand name, Resin Solutions aims enhance customer confidence, streamline product selection, and further strengthen its partnerships within the sector. The Stratix™ brand trademark will be applied to a growing portfolio of materials engineered to meet the rigorous performance, quality, and reliability expectations critical to aerospace and defense applications. Among the first products to carry the designation are Resin Solutions' flagship and highly-specified aerospac
AccessPay Appoints Johan Jardevall as CEO to Lead Next Phase of Growth1.6.2026 10:00:00 CEST | Press release
-- MANCHESTER, GB / ACCESS Newswire / June 1, 2026 / AccessPay, the leading bank integration provider, today announced the appointment of Johan Jardevall as Chief Executive Officer. Johan succeeds Anish Kapoor, who will become Chairman. Anish is stepping down after more than a decade leading the company through a significant period of growth, technology transformation, and platform development. Johan brings more than 25 years of experience leading and scaling enterprise software and SaaS businesses across Europe and the UK. He has held several senior executive and CEO positions within high-growth technology companies, with expertise spanning operational leadership, customer delivery, strategic growth, and product commercialisation. Most recently, Johan served as CEO of Person Centred Software, where he led the company through a significant phase of operational and commercial growth. The leadership transition follows AccessPay's recent strategic majority investment from Accel-KKR and ma
POLARIS Laboratories Joins the Dow Coolant Care Network as Testing Provider for DOWFROST Heat Transfer Fluids28.5.2026 15:00:00 CEST | Press release
INDIANAPOLIS, IN / ACCESS Newswire / May 28, 2026 / POLARIS Laboratories® today announced Dow has selected POLARIS Laboratories® as a testing provider for DOWFROST™ LC and HD Heat Transfer Fluids used in advanced cooling systems. This collaboration reinforces Dow's commitment to helping customers move beyond reactive maintenance practices toward proactive, data-driven fluid management. DOWFROST™ Heat Transfer Fluids are engineered to support next-generation data center cooling, including direct-to-chip liquid cooling architectures. Formulated with high-purity propylene glycol and advanced inhibitor technology, these fluids enable efficient heat removal, corrosion protection, and long-term operational stability in high-performance computing environments. To meet thermal demands from Artificial Intelligence (AI) and high-density computing, monitoring liquid cooling fluid is critical to protect uptime, maintain performance and reduce operational risk. The Dow Coolant Care Network integrat
Caldwell Strengthens Financial Services and Fintech Capabilities with Addition of Alex Langridge in London28.5.2026 10:30:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / May 28, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Alex Langridge as a Partner in the firm's Financial Services Practice. Based in London, Langridge advises clients across financial services and fintech on senior executive and board appointments, succession planning, organizational design, and transformational leadership hiring. Based in London, Alex Langridge joins Caldwell's Financial Services Practice, bringing deep expertise across banking, fintech, insurance, and transformational leadership advisory. Langridge brings more than 20 years of executive search and leadership advisory experience, partnering with banks, insurers, fintechs, and private equity- and venture-backed businesses across the UK and EMEA. He is particularly known for placing P&L, operations, commercial, product, technology, and digital leaders into high-impact transformational roles, as well as for helping cli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom